Optimizing the treatment of the dry form of age-related macular degeneration

Author: N.O. Dzyuba, Ph.D., Director of the Kyiv City Center for the Diagnosis and Treatment of Vascular Dystrophic Eye Diseases, Head of the Ophthalmology Department of the Kyiv City Clinical Hospital No. 9

Age-related macular degeneration (AMD) is a chronic dystrophic process with damage to the choriocapillary layer and pigment epithelium in the area of the macula of the retina, accompanied by loss of central vision mainly in people over 50 years of age, not associated with cataracts or other eye disease (code IKH H 35.3). With age, the frequency of AMD increases 20-25 times: its signs are detected in a quarter of men and a third of women who are over 75 years old (Hageman G. S. et al., 2008; Arroyo J. G., 2018).


Thus, in the group of complex treatment of dry AMD and the additional use of Slezavit for 180 days, stabilization of visual acuity and an increase in OSCMP by 12.6% were recorded, while in the absence of therapy, visual acuity decreased by 10.3%. Indicators of OSHCMP in the control groups practically did not change.

The results of the study give reason to conclude about the effectiveness of the use of Slezavit in the complex treatment of the dry form of AMD, as indicated by a statistically significant increase in visual acuity and OSCMP.

Download article in PDF (UA)

Аренда яхты